Tebideutorexant

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Tebideutorexant
Clinical data
Other namesJNJ-61393215; JNJ-3215
Routes of
administration		Oral
Drug classOrexin receptor antagonist
Pharmacokinetic data
Elimination half-life14–25 hours[1]
Identifiers
  • {(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl}-[3-fluoro-2-(pyrimidin-2-yl)phenyl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC23H16D2F4N4O2
Molar mass460.428 g·mol−1
3D model (JSmol)
  • [2H]C1([2H])[C@H]2C[C@@H](Oc3ccc(C(F)(F)F)cn3)[C@H](C2)N1C(=O)c1cccc(F)c1-c1ncccn1
  • InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2
  • Key:HUKWIAXQBOHZIX-USKNZQBOSA-N

Tebideutorexant[2] (developmental code names JNJ-61393215, JNJ-3215) is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders.[3][4][5][6] The drug was originated and developed by Janssen Pharmaceuticals.[3]

It is an orally active compound and acts as a selective antagonist of the orexin OX1 receptor (1-SORA).[4][5][6] Preliminary clinical findings suggest that tebideutorexant may have anti-panic effects in humans.[4][5] The elimination half-life of tebideutorexant is 13.6 to 24.6 hours.[1]

As of June 2023, tebideutorexant is in phase 2 clinical trials for the treatment of major depressive disorder while no further development has been reported for treatment of panic disorder and other anxiety disorders.[3] In 2025, a phase 2a, double-blind, placebo-controlled trial in adults with major depressive disorder and anxious distress found that adjunctive tebideutorexant did not significantly improve depressive symptoms on the Hamilton Rating Scale for Depression or anxiety on the Hamilton Anxiety Rating Scale compared with placebo.[7]

See also

[edit | edit source]

References

[edit | edit source]
  1. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  4. ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  5. ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  6. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  7. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://70.231.62.181/index.php?title=Tebideutorexant&oldid=11776893"